Compare Novartis AG (NVS) vs UDR Inc. Common Stock (UDR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs UDR Inc. Common Stock — how do they compare? Novartis AG trades at $148.84 (market cap $279.90B), while UDR Inc. Common Stock trades at $33.96 (market cap $10.91B). The key difference: Novartis AG is far larger — about 25.7× UDR Inc. Common Stock's market cap, and UDR Inc. Common Stock pays the higher dividend (5.12%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and UDR Inc. Common Stock for 0 Days on average.
| NVS | UDR | |
|---|---|---|
Market Cap | $279.90B | $10.91B |
Volume | 1,647,300 | 3,347,873 |
Sector | Health | Real Estate |
52-Week High | $168.62 | $41.24 |
52-Week Low | $121.80 | $33.27 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $321.22B | $16.95B |
Dividend Yield | 3.23% | 5.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $142.41, down 0.99% with a bearish technical signal despite strong fundamentals including 74.74% gross margins and 30.55% ROE. Recent Q2 2026 EPS beat expectations at $2.41 versus $2.17, though Q1 missed. The company announced a $7.8B licensing deal with China's Abogen for mRNA therapy, while facing clinical setbacks in ALS drug development and investor scrutiny over M&A strategy.
The stock presents a mixed outlook with solid profitability and growth potential from new deals, but technical weakness and recent trial failures pose near-term risks. Analyst consensus at $146 target suggests modest upside, though bearish sentiment from 68% hold ratings indicates caution amid pipeline uncertainties and competitive pressures in pharma.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About UDR Inc. Common Stock
UDR, Inc. is a self-administered real estate investment trust that owns, operates, develops, and redevelops multifamily apartment communities across targeted US markets. The company generates income primarily through leasing apartment homes, with a portfolio concentrated in coastal and Sunbelt metropolitan areas.
Read more on UDR →
